Sana Biotechnology To Reduce Near-Term Spend On Its Fusogen Platform For In Vivo Gene Delivery, Which Postpones Planned SG299 IND
Portfolio Pulse from Benzinga Newsdesk
Sana Biotechnology has announced plans to reduce near-term spending on its Fusogen platform for in vivo gene delivery. This decision will postpone the planned Investigational New Drug (IND) application for SG299.
October 10, 2023 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sana Biotechnology's decision to reduce spending on its Fusogen platform will delay the IND application for SG299, potentially impacting the company's stock price.
Sana Biotechnology's decision to reduce spending on its Fusogen platform will delay the IND application for SG299. This could potentially slow down the company's progress in gene therapy development, which may negatively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100